A0A024R0H7 (A0A024R0H7_HUMAN) Homo sapiens (Human)

Methylosome protein WDR77 UniProtKBInterProInteractive Modelling

342 aa; Sequence (Fasta) ; 1 identical sequence: Homo sapiens: Q9BQA1

Available Structures

64 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Crystal structure of PRMT5:MEP50 with EPZ015866 and sinefungin Heteromer
O14744; Q9BQA1;
16-328
100SFG;4Z2;GOL;
Crystal structure of PRMT5:MEP50 with Compound 15 and sinefungin Heteromer
O14744; Q9BQA1;
16-328
100SFG;5QL;GOL;
Crystal structure of PRMT5:MEP50 with Compound 9 and sinefungin Heteromer
O14744; Q9BQA1;
16-328
100SFG;5QH;GOL;
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (compound (M)-31) Heteromer
O14744; Q9BQA1;
19-329
100.0MTA;85E;
PRMT5/MEP50 with compound 30 bound Heteromer
O14744; Q9BQA1;
19-329
100.097L;MTA;
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 34 Heteromer
O14744; Q9BQA1;
18-328
100EDO;WFS;
PRMT5-MEP50 Complexed with SAM Heteromer
O14744; Q9BQA1;
18-328
10015×EDO;CL;SAM;
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 72 Heteromer
O14744; Q9BQA1;
18-328
100EDO;WFV;
PRMT5/MEP50 with compound 29 bound Heteromer
O14744; Q9BQA1;
19-329
100.097X;MTA;
PRMT5:MEP50 Complexed with Cyclonucleoside Compound 1 Heteromer
O14744; Q9BQA1;
18-328
100EDO;LB3;
PRMT5/MEP50 crystal structure with MTA and MRTX-1719 bound Heteromer
O14744; Q9BQA1;
19-329
100.0MTA;85K;
PRMT5/MEP50 crystal structure with MTA and an achiral, class 1, non-atropisomeric inhibitor bound Heteromer
O14744; Q9BQA1;
19-329
100.0NXF;MTA;
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJB44355437 Heteromer
O14744; Q9BQA1;
19-329
100.0U6K;EPE;EDO;PEG;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
19-328
100MTA;UNL;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
19-328
100MTA;UNL;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
19-328
100MTA;UNL;GOL;
Human PRMT5:MEP50 structure with Fragment (Example 18) and MTA Bound Heteromer
O14744; Q9BQA1;
19-328
100MTA;JYX;GOL;
Crystal structure of PRMT5:MEP50 in complex with MTA Heteromer
O14744; Q9BQA1;
19-328
100MTA; 10×EDO;GOL;PEG;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
19-328
100MTA;UNL;GOL;
Crystal structure of PRMT5:MEP50 with EPZ015666 and sinefungin Heteromer
O14744; Q9BQA1;
19-328
100SFG;3XV;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
19-328
100MTA;UNL;GOL;CL;
Crystal structure of PRMT5:MEP50 with Compound 10 and SAM Heteromer
O14744; Q9BQA1;
19-328
100SAM;5QK;GOL;
HUMAN PRMT5:MEP50 Crystal Structure With MTA and Fragment Bound Heteromer
O14744; Q9BQA1;
19-328
100MTA;GOL;UNL;
PRMT5:MEP50 complexed with inhibitor PF-06939999 Heteromer
O14744; Q9BQA1;
20-329
100.0ZR1;
PRMT5:MEP50 Complexed with 5,5-Bicyclic Inhibitor Compound 4 Heteromer
O14744; Q9BQA1;
19-328
100WFM; 10×EDO;CL;PEG;
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 8 Heteromer
O14744; Q9BQA1;
19-328
100QKY;EDO;GOL;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 1 Heteromer
O14744; Q9BQA1;
19-328
100MTA;A1AAS;EDO;CL;
HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound Heteromer
O14744; Q9BQA1;
20-329
100.0PJ0;MTA;SO4;EDO;PEG;CL;
PRMT5:MEP50 Complexed with Allosteric Inhibitor Compound 1a Heteromer
O14744; Q9BQA1;
19-328
100QL1;
PRMT5:MEP50 complexed with inhibitor PF-06855800 Heteromer
O14744; Q9BQA1;
20-329
100.0ZR4;
Crystal Structure of the human PRMT5:MEP50 Complex Heteromer
O14744; P62805; Q9BQA1;
21-329
100.00XU;
Human PRMT5 in complex with AZ compound 12 Heteromer
O14744; Q9BQA1;
21-329
100.0A1H76;MTA;SO4;
Human PRMT5 in complex with AZ compound 28 Heteromer
O14744; Q9BQA1;
21-329
100.0A1H73;MTA;SO4;
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ44064146 Heteromer
O14744; Q9BQA1;
21-329
100.0K8H;
Human PRMT5 in complex with AZ compound 21 Heteromer
O14744; Q9BQA1;
21-329
100.0A1H8B;MTA;SO4;
Human PRMT5 in complex with AZ compound 1 Heteromer
O14744; Q9BQA1;
21-329
100.0A1H8A;MTA;SO4;
CRYSTAL STRUCTURE OF THE HUMAN PRMT5:MEP50 COMPLEX with JNJ45031882 Heteromer
O14744; Q9BQA1;
21-329
100.0K8N;
Structure of PRMT5:MEP50 in complex with LLY-283, a potent and selective inhibitor of PRMT5, with a… Heteromer
O14744; Q9BQA1;
21-329
100.0F5J;
AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives anti-tumor activity preclinically… Heteromer
O14744; Q9BQA1;
21-329
100GOL;DMS;A1ATH;MTA;
PRMT5 bound to the PBM peptide from pICln Heteromer
O14744; P54105; Q9BQA1;
21-329
100SFG;ACE;
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAH Heteromer
O14744; Q9BQA1;
20-328
100SAH;3XV;
Cryo-EM structures and computational analysis for enhanced potency in MTA-synergic inhibition of hu… Heteromer
O14744; Q9BQA1;
21-329
100.0P2R;MTA;
Crystal Structure of PRMT5:MEP50 in complex with MTA and H4 peptide Heteromer
O14744; P62805; Q9BQA1;
21-328
100.0MTA;
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase (PRMT5) Inhibitors Heteromer
O14744; Q9BQA1;
21-328
100.0CUX;DMS;EDO;
Cryo-EM structure of the apo form of human PRMT5:MEP50 complex at a resolution of 3.4 angstrom Heteromer
O14744; Q9BQA1;
23-329
100.0
PRMT5 bound to PBM peptide from Riok1 Heteromer
O14744; Q9BQA1; Q9BRS2;
23-328
100.0SFG;
PRMT5:MEP50 complexed with adenosine Heteromer
O14744; Q9BQA1;
24-329
100.0ADN;
PRMT5/MEP50 crystal structure with MTA and a phthalazinone inhibitor bound (Compound 9) Heteromer
O14744; Q9BQA1;
23-328
100.0MTA;84W;
CryoEM structure of PRMT5 bound to covalent PBM-site inhibitor BRD-6988 Heteromer
O14744; Q9BQA1;
23-328
100.0YJG;
Structure of the methylosome-Lsm10/11 complex Heteromer
O14744; P83369; Q61189; Q9BQA1;
23-328
100.0ADN;
Human PRMT5:MEP50 structure with Fragment 3 and MTA Bound Heteromer
O14744; Q9BQA1;
24-328
100.0PWX;MTA;
Human PRMT5:MEP50 structure with Fragment 4 and MTA Bound Heteromer
O14744; Q9BQA1;
25-329
100.0PUI;MTA;PEG;CL;
Crystal structure of PRMT5:MEP50 with EPZ015666 and SAM Heteromer
O14744; Q9BQA1;
24-328
100.0SAM;3XV;GOL;
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06939999 Heteromer
O14744; Q9BQA1;
26-329
100.0ZR1;
PRMT5/MEP50 crystal structure with MTA and phthalazinone fragment bound Heteromer
O14744; Q9BQA1;
27-329
100.0CL;NA;EDO;81X;MTA;
Crystal structure of PRMT5:MEP50 with Compound 8 and sinefungin Heteromer
O14744; Q9BQA1;
26-328
100SFG;5QJ; 16×GOL;
PRMT5(M420T mutant):MEP50 complexed with inhibitor PF-06855800 Heteromer
O14744; Q9BQA1;
27-329
100.0ZR4;
Crystal structure of PRMT5:MEP50 in complex with MTA and TNG908 Heteromer
O14744; Q9BQA1;
26-328
100MTA;A1AAV;PEG;EDO;CL;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 23 Heteromer
O14744; Q9BQA1;
26-328
100MTA;A1AAT; 20×EDO;
Human PRMT5:MEP50 structure with Fragment 1 and MTA Bound Heteromer
O14744; Q9BQA1;
27-329
100.0PWL;MTA;PEG;EDO;
PRMT5 complex bound to covalent PBM inhibitor BRD6711 Heteromer
O14744; Q9BQA1;
27-328
100.0QN4;CL;SFG;GOL;
PRMT5/MEP50 crystal structure with sinefungin bound Heteromer
O14744; Q9BQA1;
27-328
100.0SFG;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 24 Heteromer
O14744; Q9BQA1;
27-328
100MTA;A1AAU;GOL;CL;
Crystal structure of PRMT5:MEP50 in complex with MTA and oxamide compound 28 Heteromer
O14744; Q9BQA1;
28-328
100MTA;A1AAR;CL;GOL;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
5c9z.1.Bmonomer0.9016-328
100.00